newsfilter
← Latest News
Business Wire·

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

VRDN
  • Viridian Therapeutics, Inc. priced an underwritten public offering of 11,425,000 shares of common stock at $22.00 per share.
  • The company granted underwriters a 30-day option to purchase an additional 1,713,750 shares at the public offering price.
  • Gross proceeds from the offering are expected to be approximately $251,350,000 before deducting underwriting discounts, commissions, & offering expenses.
  • The offering is expected to close on or about October 23, 2025, subject to customary closing conditions.
  • Viridian intends to use the net proceeds to fund commercial launch activities for veligrotug & VRDN-003, research & development, working capital, & general corporate purposes.
  • Jefferies, Leerink Partners, Evercore ISI, & Stifel are acting as joint book-running managers, while Wedbush PacGrow is the co-manager.
  • Viridian's veligrotug (VRDN-001) program includes two positive Phase 3 trials (THRIVE & THRIVE-2) for thyroid eye disease.
  • The company is advancing VRDN-003 as a potential best-in-class subcutaneous therapy for thyroid eye disease through two ongoing Phase 3 trials (REVEAL-1 & REVEAL-2).
  • Viridian is also developing a portfolio of FcRn inhibitors, including VRDN-006 & VRDN-008, for multiple autoimmune diseases.